BeyondSpring (NASDAQ:BYSI) Trading Down 2.4% – Time to Sell?

Posted by James Quigley on Nov 5th, 2025

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s share price traded down 2.4% during mid-day trading on Tuesday . The company traded as low as $1.94 and last traded at $2.02. 18,623 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 36,839 shares. The stock had previously closed at $2.07.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of BeyondSpring in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Get Our Latest Report on BeyondSpring

BeyondSpring Price Performance

The firm has a market capitalization of $81.47 million, a PE ratio of -20.20 and a beta of 0.24. The firm has a 50-day simple moving average of $1.83 and a 200-day simple moving average of $1.96.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.04) earnings per share for the quarter.

Institutional Investors Weigh In On BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC raised its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,212 shares of the company’s stock after buying an additional 231,844 shares during the quarter. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 40.29% of the company’s stock.

About BeyondSpring

(Get Free Report)

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.